PepGen Inc. (PEPG)
4.36
-0.68
(-13.49%)
USD |
NASDAQ |
Nov 13, 16:00
4.30
-0.06
(-1.38%)
Pre-Market: 09:18
PepGen Enterprise Value : 212.78M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 212.78M |
| November 12, 2026 | 259.88M |
| November 11, 2026 | 275.12M |
| November 10, 2026 | 230.10M |
| November 09, 2026 | 76.34M |
| November 06, 2026 | 81.88M |
| November 05, 2026 | 71.49M |
| November 04, 2026 | 80.49M |
| November 03, 2026 | 81.19M |
| November 02, 2026 | 73.57M |
| October 30, 2026 | 74.26M |
| October 29, 2026 | 77.72M |
| October 28, 2026 | 86.03M |
| October 27, 2026 | 90.88M |
| October 26, 2026 | 83.26M |
| October 23, 2026 | 85.34M |
| October 22, 2026 | 97.81M |
| October 21, 2026 | 99.19M |
| October 20, 2026 | 109.58M |
| October 19, 2026 | 97.81M |
| October 16, 2026 | 90.88M |
| October 15, 2026 | 86.03M |
| October 14, 2026 | 71.49M |
| October 13, 2026 | 83.96M |
| October 12, 2026 | 83.26M |
| Date | Value |
|---|---|
| October 09, 2026 | 92.27M |
| October 08, 2026 | 75.64M |
| October 07, 2026 | 77.03M |
| October 06, 2026 | 70.80M |
| October 05, 2026 | 74.26M |
| October 02, 2026 | 68.72M |
| October 01, 2026 | 63.87M |
| September 30, 2026 | 78.41M |
| September 29, 2026 | 60.92M |
| September 28, 2026 | 78.24M |
| September 25, 2026 | 78.24M |
| September 24, 2026 | 84.47M |
| September 23, 2026 | 87.24M |
| September 22, 2026 | 105.25M |
| September 21, 2026 | 95.55M |
| September 18, 2026 | 96.24M |
| September 17, 2026 | 104.56M |
| September 16, 2026 | 99.71M |
| September 15, 2026 | 99.02M |
| September 14, 2026 | 104.56M |
| September 11, 2026 | 105.25M |
| September 10, 2026 | 108.02M |
| September 09, 2026 | 117.02M |
| September 08, 2026 | 121.18M |
| September 04, 2026 | 114.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Korsana Biosciences, Inc. | 1.011B |
| IRulya Therapeutics, Inc. | 79.05M |
| Q32 Bio, Inc. | -24.10M |
| Bridgebio Oncology Therapeutics, Inc. | -19.79M |
| Oncolytics Biotech, Inc. | 46.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.39M |
| Total Expenses (Quarterly) | 19.39M |
| EPS Diluted (Quarterly) | -0.28 |
| Earnings Yield | -24.34% |
| Normalized Earnings Yield | -24.34 |